iRegene Therapeutics Achieves Milestones in Neurodegenerative Disease Treatment iRegene Therapeutics has marked significant milestones in advancing cell therapies for Parkinson's and Multiple System Atrophy in the U.S. and China, showcasing their innovative strategies.

iRegene Therapeutics Achieves Milestones in Neurodegenerative Disease Treatment #China #Chengdu #Parkinson's #NouvNeu001 #iRegene

iRegene Therapeutics Unveils Promising Data from Phase I NouvNeu001 Trials Targeting Parkinson's Disease iRegene Therapeutics announces encouraging Phase I clinical data for NouvNeu001, a new therapy aiming to treat Parkinson's disease.

iRegene Therapeutics Unveils Promising Data from Phase I NouvNeu001 Trials Targeting Parkinson's Disease #China #Chengdu #Therapeutics #NouvNeu001 #iRegene

中国のiPS細胞薬開発が加速。睿健医薬「日米と肩を並べる水準に」、シリーズBで累計60億円超を調達 人工多能性幹細胞（iPS細胞、iPSC）由来のパーキンソン病治療薬を開発するスタートアップ企業「睿健医薬（iReg[…]